Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/EP300_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/EP300_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/EP300_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/EP300_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/EP300_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/EP300_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000940831 | Oral cavity | NEOLP | response to heat | 25/2005 | 110/18723 | 2.04e-04 | 2.19e-03 | 25 |
GO:004340131 | Oral cavity | NEOLP | steroid hormone mediated signaling pathway | 29/2005 | 136/18723 | 2.17e-04 | 2.29e-03 | 29 |
GO:000913232 | Oral cavity | NEOLP | nucleoside diphosphate metabolic process | 27/2005 | 124/18723 | 2.46e-04 | 2.54e-03 | 27 |
GO:00400293 | Oral cavity | NEOLP | regulation of gene expression, epigenetic | 24/2005 | 105/18723 | 2.48e-04 | 2.55e-03 | 24 |
GO:000751714 | Oral cavity | NEOLP | muscle organ development | 56/2005 | 327/18723 | 2.65e-04 | 2.70e-03 | 56 |
GO:000609624 | Oral cavity | NEOLP | glycolytic process | 20/2005 | 81/18723 | 2.69e-04 | 2.71e-03 | 20 |
GO:001908031 | Oral cavity | NEOLP | viral gene expression | 22/2005 | 94/18723 | 3.10e-04 | 3.05e-03 | 22 |
GO:000675724 | Oral cavity | NEOLP | ATP generation from ADP | 20/2005 | 82/18723 | 3.21e-04 | 3.11e-03 | 20 |
GO:004693932 | Oral cavity | NEOLP | nucleotide phosphorylation | 23/2005 | 101/18723 | 3.50e-04 | 3.37e-03 | 23 |
GO:000276422 | Oral cavity | NEOLP | immune response-regulating signaling pathway | 74/2005 | 468/18723 | 3.90e-04 | 3.63e-03 | 74 |
GO:004603132 | Oral cavity | NEOLP | ADP metabolic process | 21/2005 | 90/18723 | 4.39e-04 | 3.97e-03 | 21 |
GO:003052123 | Oral cavity | NEOLP | androgen receptor signaling pathway | 13/2005 | 44/18723 | 4.99e-04 | 4.42e-03 | 13 |
GO:006034821 | Oral cavity | NEOLP | bone development | 38/2005 | 205/18723 | 5.28e-04 | 4.64e-03 | 38 |
GO:00987512 | Oral cavity | NEOLP | bone cell development | 11/2005 | 34/18723 | 5.70e-04 | 4.96e-03 | 11 |
GO:007121424 | Oral cavity | NEOLP | cellular response to abiotic stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:010400424 | Oral cavity | NEOLP | cellular response to environmental stimulus | 55/2005 | 331/18723 | 6.38e-04 | 5.43e-03 | 55 |
GO:005160432 | Oral cavity | NEOLP | protein maturation | 50/2005 | 294/18723 | 6.46e-04 | 5.47e-03 | 50 |
GO:007147831 | Oral cavity | NEOLP | cellular response to radiation | 35/2005 | 186/18723 | 6.47e-04 | 5.47e-03 | 35 |
GO:000616532 | Oral cavity | NEOLP | nucleoside diphosphate phosphorylation | 22/2005 | 99/18723 | 6.64e-04 | 5.54e-03 | 22 |
GO:000863031 | Oral cavity | NEOLP | intrinsic apoptotic signaling pathway in response to DNA damage | 22/2005 | 99/18723 | 6.64e-04 | 5.54e-03 | 22 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
EP300 | BAS | Skin | SCCIS | AC104365.1,STX18-AS1,VASN, etc. | 1.89e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Skin/Str/TF_SCCIS/regulons_activity_in_dotplot.png) |
EP300 | STM | Thyroid | ADJ | AL096865.1,MACF1,DDX17, etc. | 5.60e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
EP300 | STM | Thyroid | PTC | AL096865.1,MACF1,DDX17, etc. | 4.33e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_PTC/regulons_activity_in_dotplot.png) |
EP300 | CD4TN | Thyroid | ADJ | SECISBP2L,NKRF,SYNE2, etc. | 3.30e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ADJ/regulons_activity_in_dotplot.png) |
EP300 | CD4TN | Thyroid | ATC | SECISBP2L,NKRF,SYNE2, etc. | 1.17e-01 | ![The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.](images/gene_regulatory/Thyroid/Str/TF_ATC/regulons_activity_in_dotplot.png) |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EP300 | SNV | Missense_Mutation | | c.5528A>C | p.Gln1843Pro | p.Q1843P | Q09472 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A2-A0T5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
EP300 | SNV | Missense_Mutation | | c.6023N>T | p.Ser2008Phe | p.S2008F | Q09472 | protein_coding | tolerated(0.06) | benign(0.203) | TCGA-BH-A0DZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
EP300 | SNV | Missense_Mutation | rs769721803 | c.1349N>T | p.Ala450Val | p.A450V | Q09472 | protein_coding | tolerated(0.07) | possibly_damaging(0.771) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
EP300 | SNV | Missense_Mutation | rs775556373 | c.5854N>G | p.Ile1952Val | p.I1952V | Q09472 | protein_coding | tolerated(0.33) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.4352N>C | p.His1451Pro | p.H1451P | Q09472 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C8-A27B-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
EP300 | SNV | Missense_Mutation | | c.4608A>T | p.Glu1536Asp | p.E1536D | Q09472 | protein_coding | tolerated(0.07) | probably_damaging(0.994) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
EP300 | SNV | Missense_Mutation | | c.2498N>T | p.Ser833Leu | p.S833L | Q09472 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.992) | TCGA-D8-A1XM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
EP300 | SNV | Missense_Mutation | | c.980C>T | p.Ala327Val | p.A327V | Q09472 | protein_coding | tolerated(0.08) | possibly_damaging(0.833) | TCGA-D8-A1XZ-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen+anastrozolum | SD |
EP300 | SNV | Missense_Mutation | novel | c.2744G>T | p.Arg915Leu | p.R915L | Q09472 | protein_coding | tolerated_low_confidence(0.64) | benign(0) | TCGA-E2-A1LK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
EP300 | SNV | Missense_Mutation | novel | c.1440N>A | p.Met480Ile | p.M480I | Q09472 | protein_coding | tolerated(0.54) | benign(0.076) | TCGA-EW-A423-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103579 | CURCUMIN | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103614 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-UNDECYLIDENEMALONATE | CHEMBL1797707 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 187051830 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 249565916 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-PENTADECYLIDENEMALONATE | CHEMBL404916 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103615 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | inhibitor | 178103578 | | |
2033 | EP300 | CLINICALLY ACTIONABLE, ENZYME, TRANSCRIPTION FACTOR COMPLEX, DRUGGABLE GENOME | | DIETHYL-2-DODECYLIDENEMALONATE | CHEMBL1797708 | 21292492 |